Drug Delivery Patents (Class 977/906)

Cross-Reference Art Collections

Liposome (Class 977/907)
  • Patent number: 9040626
    Abstract: The invention discloses novel morphology shifting micelles and amphiphilic coated metal nanofibers. Methods of using and making the same are also disclosed.
    Type: Grant
    Filed: February 1, 2012
    Date of Patent: May 26, 2015
    Assignee: The Regents of the University of California
    Inventors: Miao-Ping Chien, Nathan C. Gianneschi
  • Patent number: 9034380
    Abstract: Materials and Methods are disclosed for producing nanoparticles linked to antibacterial ligands, including antibiotics and/or molecules which bind to bacterial markers, and for the use of the nanoparticles for the treatment of conditions treatable by the antibiotic ligands.
    Type: Grant
    Filed: August 4, 2006
    Date of Patent: May 19, 2015
    Assignee: Midatech Ltd.
    Inventors: Thomas William Rademacher, Godfrey Bradman, Soledad Penades Ullate, Rafael Ojeda Martinez De Castilla
  • Patent number: 9028873
    Abstract: The present disclosure relates to compositions and methods for producing nanoparticles to provide relatively more rapid delivery of such particles across the blood-brain barrier. The nanoparticles may be formed from bis-quaternary pyridinium-aldoxime salts that may also be of a specific polymorphic structure and which may be formed in either hydrophobic or hydrophilic type liquid media. In addition, the nanoparticle for transport across the blood-brain barrier may comprise a polymeric resin encapsulating a bis-quaternary pyridinium-2-aldoxime salt.
    Type: Grant
    Filed: February 8, 2010
    Date of Patent: May 12, 2015
    Assignee: Southwest Research Institute
    Inventors: Joseph A. McDonough, Hong Dixon, Larry A. Cabell
  • Patent number: 9029355
    Abstract: In certain embodiments, the invention is directed to composition comprising stable particles comprising ganaxolone, wherein the volume weighted median diameter (D50) of the particles is from about 50 nm to about 500 nm.
    Type: Grant
    Filed: November 22, 2013
    Date of Patent: May 12, 2015
    Assignee: Marinus Pharmaceuticals
    Inventors: Kenneth Shaw, Mingbao Zhang
  • Publication number: 20150125926
    Abstract: A tripartite nanodevice comprising a targeting portion, a carrier portion, and at least one molecule to be delivered is provided. In particular, a gold nanoparticle linked to a targeting protein and capable of delivering a stimulant for the treatment of respiratory or disease is described. A method of making and a method of using a device of this nature are also described.
    Type: Application
    Filed: November 6, 2014
    Publication date: May 7, 2015
    Inventors: Harry Goshgarian, Guangzhao Mao, Yanhua Zhang
  • Patent number: 9023388
    Abstract: A high-efficacy, long-acting formulation of silibinin, comprising silibinin solid dispersion, silibinin-loaded silica nanoparticles, slow-release matrix material and release enhancer, wherein the mass ratio of these components is silibinin solid dispersion:silibinin-loaded silica nanoparticles:slow-release matrix material:release enhancer=1:0.5˜1.25:0.1˜0.3:0.1˜0.3; the drug loading rate of the said silibinin-loaded silica nanoparticles is 51.29˜51.77%; the said silibinin solid dispersion contains povidone K30, soybean lecithin, acrylic resin IV, wherein the mass ratio between silibinin and other medical accessories is silibinin:povidone K30:soybean lecithin:acrylic resin IV=1:1˜3:0.3˜0.8:0.2˜0.5. Compared with the existing formulations, the half life of the high-efficacy, long-acting formulation of silibinin disclosed in this invention is 14.8 times longer while the mean residence time (MRT) of which is 4.
    Type: Grant
    Filed: November 23, 2009
    Date of Patent: May 5, 2015
    Assignee: Jiangsu University
    Inventors: Ximing Xu, Jiangnan Yu, Xia Cao, Yuan Zhu
  • Patent number: 9023886
    Abstract: Provided are compositions and methods for preparation and administration of an oral nanosuspension of a poorly soluble drug with improved bioavailability. The method is optimized through microfluidization process with water soluble polymeric excipients in the absence of surfactants.
    Type: Grant
    Filed: November 9, 2010
    Date of Patent: May 5, 2015
    Assignee: Celgene Corporation
    Inventors: Ming J. Chen, Ho-Wah Hui, Thomas Lee, Paul Kurtulik, Sekhar Surapaneni
  • Patent number: 9017728
    Abstract: Disclosed are stable corticosteroid nanoparticulate formulations, methods of making and therapeutic uses thereof.
    Type: Grant
    Filed: May 6, 2013
    Date of Patent: April 28, 2015
    Assignee: Marinus Pharmaceuticals
    Inventors: Kenneth Shaw, Mingbao Zhang
  • Patent number: 9012519
    Abstract: The present invention relates to a pharmaceutical composition comprising a pharmaceutical agent and a pharmaceutically acceptable carrier, which carrier comprises a protein, for example, human serum albumin and/or deferoxamine. The human serum albumin is present in an amount effective to reduce one or more side effects associated with administration of the pharmaceutical composition. The invention also provides methods for reducing one or more side effects of administration of the pharmaceutical composition, methods for inhibiting microbial growth and oxidation in the pharmaceutical composition, and methods for enhancing transport and binding of a pharmaceutical agent to a cell.
    Type: Grant
    Filed: February 26, 2013
    Date of Patent: April 21, 2015
    Assignee: Abraxis Bioscience, LLC
    Inventors: Neil P. Desai, Patrick Soon-Shiong, Vuong Trieu
  • Patent number: 9012518
    Abstract: The present invention relates to a pharmaceutical composition comprising a pharmaceutical agent and a pharmaceutically acceptable carrier, which carrier comprises a protein, for example, human serum albumin and/or deferoxamine. The human serum albumin is present in an amount effective to reduce one or more side effects associated with administration of the pharmaceutical composition. The invention also provides methods for reducing one or more side effects of administration of the pharmaceutical composition, methods for inhibiting microbial growth and oxidation in the pharmaceutical composition, and methods for enhancing transport and binding of a pharmaceutical agent to a cell.
    Type: Grant
    Filed: February 26, 2013
    Date of Patent: April 21, 2015
    Assignee: Abraxis BioScience, LLC
    Inventors: Neil P. Desai, Patrick Soon-Shiong, Vuong Trieu
  • Patent number: 9005995
    Abstract: The present invention relates to a nanoscale or microscale particle for encapsulation and delivery of materials or substances, including, but not limited to, cells, drugs, tissue, gels and polymers contained within the particle, with subsequent release of the therapeutic materials in situ, methods of fabricating the particle by folding a 2D precursor into the 3D particle, and the use of the particle in in-vivo or in-vitro applications. The particle can be in any polyhedral shape and its surfaces can have either no perforations or nano/microscale perforations. The particle is coated with a biocompatible metal, e g gold, or polymer e g parvlene, layer and the surfaces and hinges of the particle are made of any metal or polymer combinations.
    Type: Grant
    Filed: March 6, 2014
    Date of Patent: April 14, 2015
    Assignee: The Johns Hopkins University
    Inventors: David H. Gracias, Timothy Gar-Ming Leong, Hongke Ye
  • Patent number: 8999362
    Abstract: The present invention relates to novel nanoencapsulated compositions, methods for making such compositions, and methods of repelling insects and other arthropod pests away from animals, including humans. The present invention has particular, though not sole, application to repelling insects including flies and mosquitoes. The inventive compositions may be used to repel arthropods from animals, humans, plants, soil, or building structures. The formulations also prevent illness and disease caused by insect/pest-borne vectors, and provide safer, more effective alternatives to existing repellents.
    Type: Grant
    Filed: January 28, 2013
    Date of Patent: April 7, 2015
    Assignee: Merial, Inc.
    Inventors: Jean Delaveau, Audrey Minost, Hatem Fessi, Marie-Alexandrine Bolzinger, Abdelhamid Elaissari
  • Publication number: 20150094647
    Abstract: Exemplary methods of opening pores and moving molecules into tissue comprising, applying plasma to the surface of tissue and applying a carrier including one or more molecules to the surface of the tissue are disclosed herein.
    Type: Application
    Filed: September 29, 2014
    Publication date: April 2, 2015
    Applicant: EP Technologies LLC
    Inventors: Sameer Kalghatgi, Daphne Pappas Antonakas, Tsung-Chan Tsai, Robert L. Gray
  • Patent number: 8980326
    Abstract: The present invention relates to the field of polymer chemistry and more particularly to multiblock copolymers and micelles comprising the same.
    Type: Grant
    Filed: September 1, 2010
    Date of Patent: March 17, 2015
    Assignee: Intezyne Technologies, Inc.
    Inventors: Kevin N. Sill, Habib Skaff, Kurt Breitenkamp
  • Patent number: 8974770
    Abstract: The present invention discloses a method for forming a nano-bubble. The forming method is different from the oil-water emulsion reaction in the prior art. The method comprises: taking an inorganic particle as a nucleus and performing a polymer coating process to coat at least one first polymer on the surface of the nucleus to form an organic/inorganic composite particle; then removing the nucleus of the organic/inorganic composite particle by way of the dissolution of a first solvent to form an impregnated nano-particle; performing a freeze-drying process to remove the first solvent to have the impregnated nano-particle form a hollow nano-particle; and finally dissolving the hollow nano-particle in a second solvent to form the nano-bubble.
    Type: Grant
    Filed: April 15, 2009
    Date of Patent: March 10, 2015
    Assignee: Chung Yuan Christian University
    Inventors: Walter H. Chang, Cheng-An Lin, Chih-Hsien Lee, Chih-Kuang Yeh
  • Patent number: 8974826
    Abstract: A therapeutic or bioeffecting film delivery system which includes nanoparticles having actives bound to or associated with the nanoparticles and which when administered allow the active to perform a therapeutic or bioeffecting function.
    Type: Grant
    Filed: June 10, 2011
    Date of Patent: March 10, 2015
    Assignees: Monosol RX, LLC, Midatech Limited
    Inventors: Alexander M. Schobel, Garry L. Myers, Keith Joseph Kendall, Thomas Rademacher, Jan Mous, Justin N. W. Barry, Phillip Williams, Africa Garcia Barrientos
  • Patent number: 8974827
    Abstract: A pharmaceutical composition comprises nanoparticles comprising a poorly water-soluble drug, a poorly aqueous soluble non-ionizable cellulosic polymer, and a poorly aqueous soluble polymeric amphiphilic non-ionizable block copolymer.
    Type: Grant
    Filed: May 26, 2008
    Date of Patent: March 10, 2015
    Assignee: Bend Research, Inc.
    Inventors: Corey Jay Bloom, Marshall David Crew, Warren Kenyon Miller, Michael Mark Morgen, Daniel Tod Smithey
  • Patent number: 8968790
    Abstract: A nanoformulation that includes loaded nanoparticles. Each nanoparticle includes a modified chitosan polymer encapsulating at least one vitamin D derivative, at least one vitamin D metabolite, or combinations thereof. The modified chitosan polymer includes chitosan covalently linked to at least one entity selected from the group consisting of fatty acids (omega-3-fattay acids), amino acids, deoxycholic acid, alginate, arginine-alginate, hyaluronic acid, collagen, collagen-hydroxyapatite, poly(lactic-co-glycolic acid) (PLGA), and combinations thereof. A structure includes a medium and the nanoformulation, wherein the nanoparticles are dispersed in the medium. A method of using the nanoformulation to treat a disorder and improve efficacy of current therapies where resistance develop in a patient includes administering to the patient a therapeutically effective amount of the nanoformulation for treating the disorder.
    Type: Grant
    Filed: December 6, 2012
    Date of Patent: March 3, 2015
    Inventor: Shaker A. Mousa
  • Patent number: 8962032
    Abstract: There is provided a method for suppressing a pro-inflammatory immune response in a cell, comprising providing to a cell sialic acid or analogs thereof, wherein the sialic acid or analogs are presented by a substrate such that a pro-inflammatory immune response in a cell is suppressed or an anti-inflammatory immune response is increased in a cell. Further, there is provided a method of treatment of inflammatory disease in a subject in need thereof. There is also provided a drug delivery device and a biomaterial which can modulate the inflammatory response in a subject.
    Type: Grant
    Filed: December 17, 2010
    Date of Patent: February 24, 2015
    Assignee: The Queen's University of Belfast
    Inventors: Christopher Scott, James Johnston, Shaun Spence, Danny McAuley, Francois Fay
  • Patent number: 8962017
    Abstract: A high-efficacy, long-acting formulation of silymarin, comprising silymarin solid dispersion, silymarin-loaded silica nanoparticles, slow-release matrix material and release enhancer, wherein the mass ratio of these components is silymarin solid dispersion:silymarin-loaded silica nanoparticles:slow-release matrix material:release enhancer=1:0.5˜1.25:0.1˜0.3:0.1˜0.3; the drug loading rate of the said silymarin-loaded silica nanoparticles is 51.95%-52.87%; the said silymarin solid dispersion contains povidone K30, soybean lecithin and acrylic resin IV, and the mass ratio between silymarin and other medical accessories in silymarin solid dispersion is silymarin:povidone K30:soybean lecithin:acrylic resin IV=1:1˜3:0.3˜0.8:0.2˜0.5. Compared with the existing formulations, the half life of the high-efficacy, long-acting formulation of silymarin disclosed in this invention is 2.3 times longer while the mean residence time (MRT) of which is 9.
    Type: Grant
    Filed: November 23, 2009
    Date of Patent: February 24, 2015
    Assignee: Jiangsu University
    Inventors: Ximing Xu, Jiangnan Yu, Shanshan Tong, Yuan Zhu, Xia Cao
  • Patent number: 8962757
    Abstract: Innovative graft polymers designed for the efficient delivery of antisense molecules into biological cells and for maintaining the biological activity of these molecules while in serum and other aqueous environments are provided. Such polymers may comprise an anionic graft polymer comprising an anionic polymer backbone with pendant carboxylic acid groups and pendant chains comprising amphipathic or hydrophilic polymers covalently bonded to a portion of said pendant carboxylic acid groups. Antisense molecule delivery vectors comprising such polymers in combination with cationic agents for delivery of antisense molecules are also disclosed.
    Type: Grant
    Filed: November 26, 2008
    Date of Patent: February 24, 2015
    Assignee: Rutgers, The State University of New Jersey
    Inventors: David I. Devore, Charles Roth
  • Patent number: 8956657
    Abstract: The present disclosure generally relates to lyophilized pharmaceutical compositions comprising polymeric nanoparticles which, upon reconstitution, have low levels of greater than 10 micron size particles. Other aspects of the invention include methods of making such nanoparticles.
    Type: Grant
    Filed: April 12, 2013
    Date of Patent: February 17, 2015
    Assignee: BIND Therapeutics, Inc.
    Inventors: Greg Troiano, Young-Ho Song, Stephen E. Zale, James Wright, Christina Van Geen Hoven
  • Patent number: 8956637
    Abstract: This invention provides novel nanofiber enhanced surface area substrates and structures comprising such substrates for use in various medical devices, as well as methods and uses for such substrates and medical devices. In one particular embodiment, methods for enhancing cellular functions on a surface of a medical device implant are disclosed which generally comprise providing a medical device implant comprising a plurality of nanofibers (e.g., nanowires) thereon and exposing the medical device implant to cells such as osteoblasts.
    Type: Grant
    Filed: April 28, 2011
    Date of Patent: February 17, 2015
    Assignee: Nanosys, Inc.
    Inventors: Robert S. Dubrow, Lawrence A. Bock, R. Hugh Daniels, Veeral D. Hardev, Chunming Niu, Vijendra Sahi
  • Patent number: 8956656
    Abstract: The present invention relates to a method for producing particles of a compound of interest. In a method according to the invention a solution is provided of the compound of interest in a solvent. This solution is thickened or gelled and particles are formed. The invention further relates to a particle that is obtainable by the invention.
    Type: Grant
    Filed: November 22, 2005
    Date of Patent: February 17, 2015
    Assignee: Nano Fiber Matrices B.V.
    Inventors: Arianna Friggeri, Kjeld Jacobus Cornelis van Bommel, George Thomas Robillard
  • Patent number: 8951567
    Abstract: Discrete microstructures of predefined size and shape are prepared using sol-gel phase-reversible hydrogel templates. An aqueous solution of hydrogel-forming material is covered onto a microfabricated silicon wafer master template having predefined microfeatures, such as pillars. A hydrogel template is formed, usually by lowering the temperature, and the formed hydrogel template is peeled away from the silicon master template. The wells of predefined size and shape on the hydrogel template are filled with a solution or a paste of a water-insoluble polymer, and the solvent is removed to form solid structures. The formed microstructures are released from the hydrogel template by simply melting the hydrogel template in water. The microstructures are collected by centrifugation. The microstructures fabricated by this method exhibit pre-defined size and shape that exactly correspond to the microwells of the hydrogel template.
    Type: Grant
    Filed: September 27, 2008
    Date of Patent: February 10, 2015
    Assignee: Akina, Inc.
    Inventors: Kinam Park, Ghanashyam Acharya, Haesun Park
  • Patent number: 8951547
    Abstract: An ocular drug delivery system comprising a photocaged drug comprising a therapeutic agent that is rendered biologically inactive by being coupled to a protective ligand or caging group by a photocleavable bond, with the therapeutic agent being capable of being activated and/or released in response to a predetermined wavelength and/or intensity of light which breaks the photocleavable bond.
    Type: Grant
    Filed: July 11, 2013
    Date of Patent: February 10, 2015
    Assignee: Lumemed Limited
    Inventor: Alan Whitmore
  • Patent number: 8945627
    Abstract: The invention provides biocompatible micelles loaded with one or more active agents. The micelles can encapsulate anticancer drugs such as gossypol, and combinations of drugs, such as gossypol and paclitaxel, gossypol and 17-AAG, gossypol and cyclopamine, gossypol, paclitaxel, and 17-AAG, and gossypol, paclitaxel, and cyclopamine. The micelle compositions provide effective solubilization of difficult to solubilize drug combinations without the need for additional surfactants that can be toxic to patients. Thus, the invention provides stable and biocompatible drug formulations that improve bioavailability without causing toxicity.
    Type: Grant
    Filed: May 4, 2012
    Date of Patent: February 3, 2015
    Assignee: Wisconsin Alumni Research Foundation
    Inventors: Glen S. Kwon, Ho-Chul Shin, Hyunah Cho
  • Patent number: 8940333
    Abstract: An amphiphilic block copolymer is disclosed. The amphiphilic block copolymer includes one or more hydrophilic polymers, one or more hydrophobic polymer, and one or more zwitterions. The invention also provides a nanoparticle and carrier including the amphiphilic block copolymer for delivery of water insoluble drugs, growth factors, genes, or water insoluble cosmetic substances.
    Type: Grant
    Filed: March 21, 2008
    Date of Patent: January 27, 2015
    Assignee: Industrial Technology Research Institute
    Inventors: Ming-Fa Hsieh, Hsuen-Tseng Cha'ng, Chin-Fu Chen, Yuan-Chia Chang, Pei Kan, Tsai-Yu Lin
  • Patent number: 8940337
    Abstract: A transparent polymeric nanocomposite hydrogel is provided, wherein the polymeric nanocomposite hydrogel is made from a water insoluble polymer, i.e. poly(2-hydroxyethyl methacrylate) (PHEMA) or/and crosslinked PHEMA and a water insoluble nanofiber, i.e., bacterial cellulose (BC). Disclosed is a synthetic route for polymeric nanocomposites hydrogels. The preferred polymeric nanocompositions are produced through free radical polymerization of HEMA monomer in the presence of bacterial cellulose with an assistance of ultrasound to enhance the mixing of bacterial cellulose, initiator, and the monomers. The polymeric nanocomposite hydrogel is then formed by immersion of the dry polymeric nanocomposite in water. Disclosed is a high transmittance polymer nanocomposite hydrogel with a preferred BC loading less than 0.1%, water content of about 40% in weight, good mechanical integrity and strength.
    Type: Grant
    Filed: December 23, 2010
    Date of Patent: January 27, 2015
    Assignee: Axcelon Biopolymers Corporation
    Inventors: Xinsheng Li, Wankei Wan, Chandrakant J. Panchal
  • Patent number: 8936780
    Abstract: A composition including a solution suitable for introduction into a blood vessel comprising particles including a treatment agent and a tunable stimuli-responsive polymer. A method including introducing a delivery device into a blood vessel; and introducing a solution into the blood vessel, the solution including particles comprising a treatment agent and a tunable stimuli-responsive polymer. A method including combining a treatment agent and a tunable stimuli-responsive polymer; and forming particles of the combination suitable for delivery through a blood vessel.
    Type: Grant
    Filed: August 30, 2006
    Date of Patent: January 20, 2015
    Assignee: Advanced Cardiovascular Systems, Inc.
    Inventors: Gina Zhang, Jessica Renee DesNoyer, Gordon Stewart, Maricela Kezis, Syed Faiyaz Ahmed Hossainy
  • Patent number: 8927019
    Abstract: The present invention provides methods of treating recurrent cancer (such as recurrent ovarian, peritoneal, or fallopian tube cancer) in an individual, comprising administering to the individual an effective amount of a composition (such as Nab-paclitaxel or Abraxane®) comprising nanoparticles comprising a taxane and a carrier protein.
    Type: Grant
    Filed: June 2, 2008
    Date of Patent: January 6, 2015
    Assignee: Abraxis Bioscience, LLC
    Inventors: Neil P. Desai, Patrick Soon-Shiong
  • Patent number: 8926946
    Abstract: A system for targeted delivery of agents (e.g., molecular probes, diagnostic agents, therapeutic agents, imaging agents, research or analytical compounds, enzymes, peptides, proteins, lipids, lipoproteins, sugars, hormones, vitamins, nucleic acids, viruses, bacteria, and/or cells) including use of a composition containing the agent and a targeting moiety, specific for a determinant at the target location. An exemplary composition of the system includes a targeting moiety of one of peptides ?3, 2?3, 3?3, A1, B7, B8, B9, B1O, and D6, specific for targeting ICAM-I. The system enables effective, versatile, and safe targeting and transport of agents. The system is useful in research applications, as well as in the context of translational science and clinical interventions.
    Type: Grant
    Filed: June 4, 2010
    Date of Patent: January 6, 2015
    Assignee: University of Maryland, College Park
    Inventors: Silvia Muro Galindo, Ming Meng, Carmen Garnacho Montero
  • Patent number: 8916203
    Abstract: The present disclosure generally relates to lyophilized pharmaceutical compositions comprising polymeric nanoparticles which, upon reconstitution, have low levels of greater than 10 micron size particles. Other aspects of the invention include methods of making such nanoparticles.
    Type: Grant
    Filed: October 30, 2012
    Date of Patent: December 23, 2014
    Assignee: BIND Therapeutics, Inc.
    Inventors: Greg Troiano, Young-Ho Song, Stephen E. Zale, James Wright, Christina Van Geen Hoven
  • Patent number: 8916197
    Abstract: The present invention pertains to a bone marrow-directing drug delivery material that includes at least one fine particle, wherein the fine particle includes an anionic moiety on a surface of the particle. Also disclosed are uses of the material set forth herein for the prevention, treatment, or diagnosis of a disease of bone, cartilage, bone marrow, or a joint. Also disclosed are methods of preventing, treating, or diagnosing a disease of bone, cartilage, bone marrow, or a joint in a subject, involving administering to the subject a pharmaceutically effective amount of the material of the present invention.
    Type: Grant
    Filed: June 5, 2006
    Date of Patent: December 23, 2014
    Assignees: The Board of Regents of the University of Texas System, Waseda University
    Inventors: Keitaro Sou, Shinji Takeoka, Eishun Tsuchida, Beth A. Goins, William T. Phillips
  • Patent number: 8916606
    Abstract: The present invention pertains to therapeutic compositions that comprise: (1) a nanovector, (2) an active agent; and (3) a targeting agent, wherein the active agent and the targeting agent are non-covalently associated with the nanovector. The present invention also pertains to methods of treating various conditions in a subject by utilizing the above-described therapeutic compositions. Methods of making the therapeutic compositions are also a subject matter the present invention.
    Type: Grant
    Filed: October 27, 2010
    Date of Patent: December 23, 2014
    Assignees: William Marsh Rice University, Board of Regents, The University of Texas System
    Inventors: James M. Tour, Jacob Berlin, Tam Pham, Jeffrey N. Myers, Daisuke Sano
  • Patent number: 8911766
    Abstract: The current invention is directed to compositions comprising a plurality of particles including nanoshells or a medical device with a coating including nanoshells allowing for triggered drug release. Methods of treatment with such compositions are also included.
    Type: Grant
    Filed: June 26, 2009
    Date of Patent: December 16, 2014
    Assignee: Abbott Cardiovascular Systems Inc.
    Inventors: Syed F. A. Hossainy, John J. Stankus, Dariush Davalian
  • Patent number: 8906409
    Abstract: Novel acoustically sensitive drug carrying particles comprising non-lamellar forming lipids are disclosed, as well as uses and methods thereof. The drug carrying particles accumulate in the diseased target tissue and efficiently release their payload upon exposure to acoustic energy.
    Type: Grant
    Filed: June 8, 2010
    Date of Patent: December 9, 2014
    Assignee: Epitarget AS
    Inventors: Cecilia Leal Lauten, Karen Sibylla Røgnvaldsson, Sigrid Fossheim, Esben A. Nilssen, Tove J. Evjen
  • Patent number: 8900624
    Abstract: The present invention comprises methods and compositions for antimicrobial silver compositions comprising silver nanoparticles. The present invention further comprises compositions for preparing silver nanoparticles comprising at least one stabilizing agent, one or more silver compounds, at least one reducing agent and a solvent. In one aspect, the stabilizing agent comprises a surfactant or a polymer. The polymer may comprise polymers such as polyacrylamides, polyurethanes, and polyamides. In one aspect, the silver compound comprises a salt comprising a silver cation and an anion. The anion may comprise saccharinate derivatives, long chain fatty acids, and alkyl dicarboxylates. The methods of the present invention comprise treating devices with the silver nanoparticle compositions, including, but not limited to, such devices as woven wound care materials, catheters, patient care devices, and collagen matrices.
    Type: Grant
    Filed: August 1, 2005
    Date of Patent: December 2, 2014
    Assignee: Kimberly-Clark Worldwide, Inc.
    Inventors: Bhalchandra M. Karandikar, Bruce L. Gibbins, Ken A. Cornell
  • Patent number: 8895069
    Abstract: The present invention relates to a drug delivery composition comprising a hyaluronic acid-peptide conjugate micelle and a production method thereof. According to the drug delivery composition and the production method of the drug-loaded, hyaluronic acid-peptide conjugate micelle of the present invention, the reaction for encapsulating can proceed in a mixed solvent of an aqueous solvent and an organic solvent. Therefore, the present invention can be applied to various types of water-insoluble active components and the biocompatible and biodegradable derivative can encapsulate a drug to provide a drug-loaded micelle, which is safe to be applied for human bodies. Moreover, the micelle has a therapeutic effect from the peptide contained therein, which can act in combination with the drug as packing therein. Therefore, the drug delivery composition and its production method can be utilized in the field of producing a sustained release formulation with an extended duration of the medicinal effect.
    Type: Grant
    Filed: December 15, 2011
    Date of Patent: November 25, 2014
    Assignee: Postech Academy-Industry Foundation
    Inventors: Sei Kwang Hahn, Choun-Ki Joo, Yoon Keun Kim, Seung Kew Yoon, Eun Ju Oh, Ki Su Kim, Hyemin Kim, Kitae Park, Jeong-A Yang, Jun-Sub Choi, You Me Tae, Wonhee Hur
  • Patent number: 8889192
    Abstract: The present invention discloses a magnetic nanomedicine for inhibiting/treating human prostate cancer, which comprises a core containing a magnetic particle having a diameter of less than 10 nm; a shell made of a carboxylated polyaniline and encapsulating the core; and a medicine covalently linked to the shell and able to inhibit/treat prostate cancer. The magnetic nanomedicine of the present invention not only has superior thermal stability and but also has water solubility higher than that of the conventional anti-prostate cancer medicine. Further, the magnetic nanomedicine of the present invention can be magnetically conducted to the cancer area to increase the local concentration of medicine and enhance the therapeutic effect.
    Type: Grant
    Filed: July 6, 2011
    Date of Patent: November 18, 2014
    Assignee: Chang Gung University
    Inventors: Mu-Yi Hua, Hung-Wei Yang, Cheng-Keng Chuang, See-Tong Pang, Hao-Li Liu, Rung-Ywan Tsai, Kun-Lung Chuang
  • Patent number: 8889175
    Abstract: The present technology provides a nanoparticulate in-situ gelling vitreous substitute, which is a liquid at room temperature to aid easy administration, such as e.g. through a small needle incision, and forms a gel within the eye, which is hydrophilic in nature, similar to the natural vitreous. The vitreous substitute formulation may include a water-soluble natural or synthetic polymer and a gelling-agent which are blended together in the presence of a cross linker, to form a gel having the properties of the vitreous humor. The process of cross linking and gelation may occur in-situ. This can be achieved by dispensing to the eye, different components of the vitreous substitute in liquid state, along with the cross linking agent.
    Type: Grant
    Filed: December 21, 2012
    Date of Patent: November 18, 2014
    Assignee: Indian Institute of Technology Bombay
    Inventors: Rinti Banerjee, Edmund Carvalho
  • Patent number: 8883216
    Abstract: Compositions and methods for heavy metal remediation are disclosed. The compositions contain ceramic nanoparticulate cation exchangers specific for at least one heavy metal as well as at least one carrier, typically a thickener, a gel forming agent and/or a cross-binding agent. The compositions may also contain chelating agents as well as beneficial agents such as vitamins and pharmaceuticals, with or without the ceramic nanoparticulate cation exchangers.
    Type: Grant
    Filed: February 28, 2013
    Date of Patent: November 11, 2014
    Assignee: Red Lion Chem Tech, LLC
    Inventors: Allan D. Pronovost, Michael E. Hickey
  • Patent number: 8871269
    Abstract: The methods disclosed herein are of use for the production of controlled release compositions. In particular, the methods provide the contacting of an organic phase containing a bioactive agent and a polymer with an aqueous phase containing an organic ion to create controlled release compositions containing bioactive agents. The present invention also includes controlled release compositions including a polymer, an organic ion and a bioactive agent. The present invention also includes methods of using such controlled release compositions. The usefulness of the present invention is that the methods result in the production of controlled release compositions containing bioactive agent capable of administration in a concentrated low-dose form, having low burst and reduced production of degraded bioactive agent.
    Type: Grant
    Filed: July 15, 2004
    Date of Patent: October 28, 2014
    Assignee: Evonik Corporation
    Inventor: Gary P. Cook
  • Patent number: 8865206
    Abstract: Dermal delivery is best suited for the various skin diseases or disorders. However, the stratum corneum limits the permeation of number of suitable pharmaceutical agents for dermal delivery. Certain embodiments of the present invention include surface modified multilayered nanostructures. The modification was completed by using fatty acids enabling delivery of a significant amount of one or more pharmaceutical agent(s) into deeper layers of the epidermis and dermis to treat skin diseases or disorders. Each active pharmaceutical agent can be encapsulated into the separate layers of the nanostructures.
    Type: Grant
    Filed: December 10, 2013
    Date of Patent: October 21, 2014
    Assignee: Florida A&M University
    Inventors: Mandip Sachdeva, Punit Shah
  • Patent number: 8865216
    Abstract: Surface-modified polymeric nanoparticles (NPs), compositions for making them, and their use in drug delivery are disclosed.
    Type: Grant
    Filed: August 1, 2008
    Date of Patent: October 21, 2014
    Assignees: National Institutes of Health (NIH), U.S. Dept. of Health and Human Services (DHHS)
    Inventors: Vinod Labhasetwar, Jaspreet Vasir
  • Publication number: 20140308203
    Abstract: Provided herein are methods for delivering a molecule in situ to a cell and for treating a cancer via the in situ delivery. The methods comprise contacting or administering to the cell, as two separate components, a morpholino oligonucleotide comprising a targeting moiety followed by a single wall nanotube construct comprising second morpholino oligonucleotides complementary to the first morpholino oligonucleotides and one or both of a therapeutic or diagnostic payload molecule linked to the single wall nanotube construct. Upon self-assembly of a single wall nanotube complex via hybridization of the first morpholino and second complementary morpholino oligonucleotides at the cell, the payload molecule is delivered. Also provided is the two component self-assembly single wall nanotube system and the single wall nanotube construct comprising the second component.
    Type: Application
    Filed: June 27, 2014
    Publication date: October 16, 2014
    Inventors: David A. Scheinberg, Michael R. McDevitt, Carlos H. Villa, J. Justin Mulvey
  • Patent number: 8859002
    Abstract: The invention relates to a method for the dispersion of synthetic or natural nanoparticles and nanocomposite materials and to the use thereof in different sectors including those of ceramics, coatings, polymers, construction, paints, catalysis, pharmaceuticals and powdered materials in general.
    Type: Grant
    Filed: July 21, 2009
    Date of Patent: October 14, 2014
    Assignee: Consejo Superior De Investigaciones Cientificas
    Inventors: José Francisco Fernándezlozano, Israel Lorite Villalba, Fernando Rubio Marcos, Juan José Romero Fanego, Miguel Ángel García García-Tuñon, Adrian Quesada Michelena, Maria Soledad Martin González, José Luis Costa Kramer
  • Patent number: 8859004
    Abstract: The present invention discloses the pH-sensitive nanoparticles composed of pH-sensitive polymer, hydrophobic material, internal stabilizer, external stabilizer content and insulin drug. The present invention also includes a method for preparation of pH-sensitive nanoparticles, in particular, a multiple emulsions solvent evaporation method. The pH-sensitive nanoparticles of the present invention show good pH-sensitive property with 100-300 nanometer particle size. Significant decrease in blood glucose level is observed in streptozotocin (STZ)-induced diabetic rats and the bioavailability of insulin is more than 10% after oral administration of the insulin-loaded pH-sensitive nanoparticles.
    Type: Grant
    Filed: July 30, 2012
    Date of Patent: October 14, 2014
    Assignee: Nano and Advanced Materials Institute Limited
    Inventors: Lijuan Zhang, Li Ling, Li Ying Zhou, Zhi Min Wu, Xin Dong Guo, Wei Jiang, Qian Luo, Yu Qian
  • Patent number: 8852640
    Abstract: Embodiments include a vehicle for delivery of nitric oxide comprising: a collection of micelles having an internal micelle core that comprises a polymer with N-diazeniumdiolate comprising NO complexed with secondary amines of the polymer. Embodiments include a method of making a nitric oxide vehicle comprising dissolving a polymer that comprises secondary amines in an aqueous solution and combining the polymer with nitric oxide in the solution to form a N-diazeniumdiolate comprising the nitric oxide complexed with the secondary amines, with the formation of the N-diazeniumdiolate causing the polymer to be at least partially insoluble in the solution and to form a collection of micelles that have an internal core that comprises N-diazeniumdiolate.
    Type: Grant
    Filed: July 3, 2008
    Date of Patent: October 7, 2014
    Assignee: Ecole Polytechnique Federale de Lausanne (EPFL)
    Inventors: Jeffrey A. Hubbell, Yun Suk Jo, André van der Vlies
  • Patent number: 8853280
    Abstract: The present invention provides compositions comprising allylamine drug compounds for topical treatment of fungal infections of the skin and skin appendages. In some embodiments a positive charge and enhancers are used in the compositions to allow for increased penetration of the active ingredient through skin and skin appendages. In some embodiments the positively charged active ingredients are either dissolved in the vehicle directly or dissolved in a plurality of beads suspended in the vehicle. The present invention also provides methods for making compositions comprising an allylamine drug compound, and methods of using such compositions for the treatment of fungal infections of the skin and skin appendages.
    Type: Grant
    Filed: October 4, 2011
    Date of Patent: October 7, 2014
    Assignee: Biophile Corporation, Ltd.
    Inventors: Pichit Suvanprakorn, Panida Vayumhasuwan, Nardo Zaias